[ad_1]
On Monday, German pharmaceutical companies Biontech and Pfizer of the US will seek approval for their coronavirus vaccine in the US in November, and the European Commission said Wednesday that it would approve a contract that would allow them to acquire up to 300 million dose of the coronavirus vaccine. Of the company.
The third phase of the vaccine trial involved 43,500,000 people from six countries, and pharmaceutical companies said the risk of developing Covid-19 in vaccine recipients was more than 90 percent lower than without the vaccine.
As a result of the announcement, Pfizer shares began to skyrocket, benefiting the CEO of the company, Albert bourla which sold $ 5.56 million (almost HUF 1.7 billion) of the securities that day, Reuters reports. Bourla authorized the transaction on August 19 should the share price reach a certain level. The timing was great, the exchange rate was up 15 percent on Monday, the highest price was $ 41.99, while on Wednesday they were given $ 38.75.
[ad_2]
